Unicycive Therapeutics, Inc. (UNCY)
UNCYNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$3.69
-0.0900 (-2.38%) today
Regular session, Nov 12, 11:22 AM ET
- Market cap
- $102.79m
- P/E
- –
- EPS, last 4 quarters
- $-1.81
- Dividend yield
- –
- Day range
- $3.56 to $3.71
- 52-week range
- $3.33 to $8.74
- Average volume
- –
- Previous close
- $3.78
Analysts
6 coveringBuy6 buy, 0 hold, 0 sell
Targets a year out average $25.60, +593.8% from here
Earnings
next estimate $-0.3300Next report
Sep 2025
+33.9%
Dec 2025
-78.3%
Mar 2026
+1.8%
Jun 2026
+82.3%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$7.33m | -$7.22m | -$8.44m | -$10.14m |
| Net income | -$6.01m | -$14.67m | -$12.82m | -$1.72m |
News
8 latest- Average Analyst Price Target for Unicycive Therapeutics Rises 12.32% to $32.54Fintel · Oct 23, 2026
- Unicycive Jumps As FDA Accepts Kidney Drug Resubmission; March 2027 Decision Set RTTNews · Oct 21, 2026
- Unicycive Therapeutics (UNCY) Loses 21.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks · Oct 13, 2026
- Unicycive Resubmits OLC NDA With New Manufacturing Data To Support FDA Review; Stock Down RTTNews · Sep 29, 2026
- Unicycive Therapeutics Resubmits Oxylanthanum Carbonate NDA To FDA RTTNews · Sep 29, 2026
- Weekly Buzz: VRTX, APTX Gain FDA Nod; UNCY Disappoints; Ipsen Opens Wallet; VTGN Misses Goal RTTNews · Jul 2, 2026
- Unicycive Receives FDA Complete Response Letter For Oxylanthanum Carbonate NDA; Stock Down RTTNews · Jun 30, 2026
- Unicycive Says FDA Issues CRL For Oxylanthanum Carbonate For Hyperphosphatemia In CKD Patients RTTNews · Jun 30, 2026
The company
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive's second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- unicycive.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.